Rifaximinisarifampicinderivativewithweakerabsorptionkinetics;itinhibitsDNA-dependentRNApolymerase.Rifaximinisanansamycinantibacterialcompoundthatisclinicallyusedtotreatsmallintestinalbacterialovergrowthinsubjectswithinflammatorybowelsyndrome(IBS).
| CasNo. | 80621-81-4 |
|---|---|
| Purity | ≥98% |
| Formula | C43H51N3O11 |
| FormulaWt. | 785.88 |
| ChemicalName | [2S-(2R*,16Z,18E,20R*,21R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-[epoxypentadeca(1,11,13)trienimino]-benzofuro[4,5-e]-pyridol[1,2-a]benzimidazole-1,15(2H)-dione |
| Synonym | Rifacol;XIFAXAN;Fatroximin;Normix;Rifacol |
| MeltingPoint | 200-205°C(dec) |
| Solubility | Solubleinalcohols,ethylacetate,chloroformortoluene. |
| Appearance | ARedOrangePowder |
| StoreTemp | 4°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | R3321InfoSheetPDF |
|---|
HuhulescuS,SagelU,FiedlerA,etal.RifaximindiscdiffusiontestforinvitrosusceptibilitytestingofClostridiumdifficile.JMedMicrobiol.2011Aug;60(Pt8):1206-12.PMID:21292853.
MajewskiM,McCallumRW.Resultsofsmallintestinalbacterialovergrowthtestinginirritablebowelsyndromepatients:clinicalprofilesandeffectsofantibiotictrial.AdvMedSci.2007;52:139-42.PMID:18217406.
